IBDEI342 ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,49685,2)
;;=^5003770^F02.80
;;^UTILITY(U,$J,358.3,49686,0)
;;=G31.01^^191^2477^26
;;^UTILITY(U,$J,358.3,49686,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49686,1,3,0)
;;=3^Pick's Disease
;;^UTILITY(U,$J,358.3,49686,1,4,0)
;;=4^G31.01
;;^UTILITY(U,$J,358.3,49686,2)
;;=^329915
;;^UTILITY(U,$J,358.3,49687,0)
;;=G23.1^^191^2477^28
;;^UTILITY(U,$J,358.3,49687,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49687,1,3,0)
;;=3^Progressive Supranuclear Ophthalmoplegia
;;^UTILITY(U,$J,358.3,49687,1,4,0)
;;=4^G23.1
;;^UTILITY(U,$J,358.3,49687,2)
;;=^5003780
;;^UTILITY(U,$J,358.3,49688,0)
;;=E11.21^^191^2478^33
;;^UTILITY(U,$J,358.3,49688,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49688,1,3,0)
;;=3^Type 2 DM w/ Nephropathy
;;^UTILITY(U,$J,358.3,49688,1,4,0)
;;=4^E11.21
;;^UTILITY(U,$J,358.3,49688,2)
;;=^5002629
;;^UTILITY(U,$J,358.3,49689,0)
;;=E11.22^^191^2478^31
;;^UTILITY(U,$J,358.3,49689,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49689,1,3,0)
;;=3^Type 2 DM w/ CKD
;;^UTILITY(U,$J,358.3,49689,1,4,0)
;;=4^E11.22
;;^UTILITY(U,$J,358.3,49689,2)
;;=^5002630
;;^UTILITY(U,$J,358.3,49690,0)
;;=E11.40^^191^2478^34
;;^UTILITY(U,$J,358.3,49690,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49690,1,3,0)
;;=3^Type 2 DM w/ Neuropathy,Unspec
;;^UTILITY(U,$J,358.3,49690,1,4,0)
;;=4^E11.40
;;^UTILITY(U,$J,358.3,49690,2)
;;=^5002644
;;^UTILITY(U,$J,358.3,49691,0)
;;=E11.65^^191^2478^32
;;^UTILITY(U,$J,358.3,49691,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49691,1,3,0)
;;=3^Type 2 DM w/ Hyperglycemia
;;^UTILITY(U,$J,358.3,49691,1,4,0)
;;=4^E11.65
;;^UTILITY(U,$J,358.3,49691,2)
;;=^5002663
;;^UTILITY(U,$J,358.3,49692,0)
;;=E11.9^^191^2478^35
;;^UTILITY(U,$J,358.3,49692,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49692,1,3,0)
;;=3^Type 2 DM w/o Complications
;;^UTILITY(U,$J,358.3,49692,1,4,0)
;;=4^E11.9
;;^UTILITY(U,$J,358.3,49692,2)
;;=^5002666
;;^UTILITY(U,$J,358.3,49693,0)
;;=E03.9^^191^2478^26
;;^UTILITY(U,$J,358.3,49693,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49693,1,3,0)
;;=3^Hypothyroidism
;;^UTILITY(U,$J,358.3,49693,1,4,0)
;;=4^E03.9
;;^UTILITY(U,$J,358.3,49693,2)
;;=^5002476
;;^UTILITY(U,$J,358.3,49694,0)
;;=N18.1^^191^2478^14
;;^UTILITY(U,$J,358.3,49694,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49694,1,3,0)
;;=3^Chronic Kidney Disease,Stage 1
;;^UTILITY(U,$J,358.3,49694,1,4,0)
;;=4^N18.1
;;^UTILITY(U,$J,358.3,49694,2)
;;=^5015602
;;^UTILITY(U,$J,358.3,49695,0)
;;=N18.2^^191^2478^15
;;^UTILITY(U,$J,358.3,49695,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49695,1,3,0)
;;=3^Chronic Kidney Disease,Stage 2
;;^UTILITY(U,$J,358.3,49695,1,4,0)
;;=4^N18.2
;;^UTILITY(U,$J,358.3,49695,2)
;;=^5015603
;;^UTILITY(U,$J,358.3,49696,0)
;;=N18.3^^191^2478^16
;;^UTILITY(U,$J,358.3,49696,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49696,1,3,0)
;;=3^Chronic Kidney Disease,Stage 3
;;^UTILITY(U,$J,358.3,49696,1,4,0)
;;=4^N18.3
;;^UTILITY(U,$J,358.3,49696,2)
;;=^5015604
;;^UTILITY(U,$J,358.3,49697,0)
;;=N18.4^^191^2478^17
;;^UTILITY(U,$J,358.3,49697,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49697,1,3,0)
;;=3^Chronic Kidney Disease,Stage 4
;;^UTILITY(U,$J,358.3,49697,1,4,0)
;;=4^N18.4
;;^UTILITY(U,$J,358.3,49697,2)
;;=^5015605
;;^UTILITY(U,$J,358.3,49698,0)
;;=N18.5^^191^2478^18
;;^UTILITY(U,$J,358.3,49698,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI342 3777 printed Nov 22, 2024@17:51:33 Page 2
IBDEI342 ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,49685,2)
+2 ;;=^5003770^F02.80
+3 ;;^UTILITY(U,$J,358.3,49686,0)
+4 ;;=G31.01^^191^2477^26
+5 ;;^UTILITY(U,$J,358.3,49686,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,49686,1,3,0)
+8 ;;=3^Pick's Disease
+9 ;;^UTILITY(U,$J,358.3,49686,1,4,0)
+10 ;;=4^G31.01
+11 ;;^UTILITY(U,$J,358.3,49686,2)
+12 ;;=^329915
+13 ;;^UTILITY(U,$J,358.3,49687,0)
+14 ;;=G23.1^^191^2477^28
+15 ;;^UTILITY(U,$J,358.3,49687,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,49687,1,3,0)
+18 ;;=3^Progressive Supranuclear Ophthalmoplegia
+19 ;;^UTILITY(U,$J,358.3,49687,1,4,0)
+20 ;;=4^G23.1
+21 ;;^UTILITY(U,$J,358.3,49687,2)
+22 ;;=^5003780
+23 ;;^UTILITY(U,$J,358.3,49688,0)
+24 ;;=E11.21^^191^2478^33
+25 ;;^UTILITY(U,$J,358.3,49688,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,49688,1,3,0)
+28 ;;=3^Type 2 DM w/ Nephropathy
+29 ;;^UTILITY(U,$J,358.3,49688,1,4,0)
+30 ;;=4^E11.21
+31 ;;^UTILITY(U,$J,358.3,49688,2)
+32 ;;=^5002629
+33 ;;^UTILITY(U,$J,358.3,49689,0)
+34 ;;=E11.22^^191^2478^31
+35 ;;^UTILITY(U,$J,358.3,49689,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,49689,1,3,0)
+38 ;;=3^Type 2 DM w/ CKD
+39 ;;^UTILITY(U,$J,358.3,49689,1,4,0)
+40 ;;=4^E11.22
+41 ;;^UTILITY(U,$J,358.3,49689,2)
+42 ;;=^5002630
+43 ;;^UTILITY(U,$J,358.3,49690,0)
+44 ;;=E11.40^^191^2478^34
+45 ;;^UTILITY(U,$J,358.3,49690,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,49690,1,3,0)
+48 ;;=3^Type 2 DM w/ Neuropathy,Unspec
+49 ;;^UTILITY(U,$J,358.3,49690,1,4,0)
+50 ;;=4^E11.40
+51 ;;^UTILITY(U,$J,358.3,49690,2)
+52 ;;=^5002644
+53 ;;^UTILITY(U,$J,358.3,49691,0)
+54 ;;=E11.65^^191^2478^32
+55 ;;^UTILITY(U,$J,358.3,49691,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,49691,1,3,0)
+58 ;;=3^Type 2 DM w/ Hyperglycemia
+59 ;;^UTILITY(U,$J,358.3,49691,1,4,0)
+60 ;;=4^E11.65
+61 ;;^UTILITY(U,$J,358.3,49691,2)
+62 ;;=^5002663
+63 ;;^UTILITY(U,$J,358.3,49692,0)
+64 ;;=E11.9^^191^2478^35
+65 ;;^UTILITY(U,$J,358.3,49692,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,49692,1,3,0)
+68 ;;=3^Type 2 DM w/o Complications
+69 ;;^UTILITY(U,$J,358.3,49692,1,4,0)
+70 ;;=4^E11.9
+71 ;;^UTILITY(U,$J,358.3,49692,2)
+72 ;;=^5002666
+73 ;;^UTILITY(U,$J,358.3,49693,0)
+74 ;;=E03.9^^191^2478^26
+75 ;;^UTILITY(U,$J,358.3,49693,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,49693,1,3,0)
+78 ;;=3^Hypothyroidism
+79 ;;^UTILITY(U,$J,358.3,49693,1,4,0)
+80 ;;=4^E03.9
+81 ;;^UTILITY(U,$J,358.3,49693,2)
+82 ;;=^5002476
+83 ;;^UTILITY(U,$J,358.3,49694,0)
+84 ;;=N18.1^^191^2478^14
+85 ;;^UTILITY(U,$J,358.3,49694,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,49694,1,3,0)
+88 ;;=3^Chronic Kidney Disease,Stage 1
+89 ;;^UTILITY(U,$J,358.3,49694,1,4,0)
+90 ;;=4^N18.1
+91 ;;^UTILITY(U,$J,358.3,49694,2)
+92 ;;=^5015602
+93 ;;^UTILITY(U,$J,358.3,49695,0)
+94 ;;=N18.2^^191^2478^15
+95 ;;^UTILITY(U,$J,358.3,49695,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,49695,1,3,0)
+98 ;;=3^Chronic Kidney Disease,Stage 2
+99 ;;^UTILITY(U,$J,358.3,49695,1,4,0)
+100 ;;=4^N18.2
+101 ;;^UTILITY(U,$J,358.3,49695,2)
+102 ;;=^5015603
+103 ;;^UTILITY(U,$J,358.3,49696,0)
+104 ;;=N18.3^^191^2478^16
+105 ;;^UTILITY(U,$J,358.3,49696,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,49696,1,3,0)
+108 ;;=3^Chronic Kidney Disease,Stage 3
+109 ;;^UTILITY(U,$J,358.3,49696,1,4,0)
+110 ;;=4^N18.3
+111 ;;^UTILITY(U,$J,358.3,49696,2)
+112 ;;=^5015604
+113 ;;^UTILITY(U,$J,358.3,49697,0)
+114 ;;=N18.4^^191^2478^17
+115 ;;^UTILITY(U,$J,358.3,49697,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,49697,1,3,0)
+118 ;;=3^Chronic Kidney Disease,Stage 4
+119 ;;^UTILITY(U,$J,358.3,49697,1,4,0)
+120 ;;=4^N18.4
+121 ;;^UTILITY(U,$J,358.3,49697,2)
+122 ;;=^5015605
+123 ;;^UTILITY(U,$J,358.3,49698,0)
+124 ;;=N18.5^^191^2478^18
+125 ;;^UTILITY(U,$J,358.3,49698,1,0)
+126 ;;=^358.31IA^4^2
